
# Asthma Action Plan in Adults

Quah Lishan Jessica Associate Consultant Department of Respiratory and Critical Care Medicine Changi General Hospital, SingHealth



• No conflicts of interest





## <u>Topics</u>

- What is an AAP?
- Why use an AAP?
- How to prescribe an AAP

- Special considerations when prescribing an AAP
- Barriers and how to overcome them



# What?



Physician – prescribed

## Varies therapy depending on



End-user actually using it





#### WRITTEN ASTHMA ACTION PLAN (WAAP)

EVERY DAY ASTHMA CARE	WHEN I FEEL WORSE	IN AN ASTHMA ATTACK
My personal best peak flow is: <u>PREVENTER INHALER</u> I need to take my preventer inhaler <u>every day</u> even when I feel well. My preventer inhaler is:	<ul> <li>My symptoms are coming back (wheeze, tightness in my chest, breathlessness, cough)</li> <li>I am waking up at night</li> <li>My symptoms are interfering with my usual day-to-day activities (e.g. at work, exercising, housechores)</li> <li>I am using my reliever inhaler times a week or more</li> <li>If I am told to monitor my peak flow and it drops to below</li> </ul>	<ul> <li>My reliever inhaler is not helping or I need it more than every hours</li> <li>I find it difficult to walk or talk</li> <li>I find it difficult to breathe</li> <li>I'm wheezing a lot or I have a very tight chest or I'm coughing a lot</li> <li>If I am told to monitor my peak flow and it drops to below</li> </ul>
(insert name/colour) I should takepuff(s) in the morning and puff(s) at night	Preventer inhaler If I have <u>not</u> been using my preventer inhaler, start	THIS IS AN EMERGENCY.
RELIEVER INHALER	using it regularly again. Increase my preventer inhaler to puffs times a day for 2 weeks.	PLEASE TAKE THE FOLLOWING ACTION NOW:
I take my reliever inhaler only if I need. My reliever inhaler is: (insert name/colour) I should takepuff(s) of my reliever inhaler if any of these things happen: I'm wheezing My chest feels tight I'm finding it hard to breathe I'm coughing.	Reliever inhaler         Ventolin MDI: up to puffs every hours         Symbicort: 1 puff as needed up to a total 12 puffs/day         Standby prednisolone	<ol> <li>Sit up straight. Try to keep calm.</li> <li>Take 2 puffs of my reliever inhaler every 5minutes up to a maximum of 10 puffs</li> <li>If I do not feel better after 10 puffs, or if I feel worse at any point in time, I need to get to the nearest doctor or hospital.</li> <li>Call 995 for an ambulance if needed.</li> </ol>
<b>Other medicines</b> I should take for my asthma every day: (free text)	<ul> <li>If I have been given standby prednisolone (steroid) tablets to keep at home: take mg of prednisolone immediately and every morning for 5 days</li> <li>If I do not improve within 24 hours, I should visit a doctor for further advice.</li> <li>Alternatively, I may also contact the asthma nurse (at</li> </ul>	Affix Patient's Sticker Date WAAP given to patient:
With this daily routine I should expect/aim to have no symptoms.	within office hours) for further advice before seeing a doctor	Asthma nurse : Primary respiratory physician:

al

#### **EVERY DAY ASTHMA CARE**

My personal best peak flow is: \_

#### PREVENTER INHALER

I need to take my preventer inhaler <u>every day</u> even when I feel well.

My preventer inhaler is: (insert name/colour) I should take \_\_\_\_\_puff(s) in the morning and \_\_\_\_\_puff(s) at night

#### RELIEVER INHALER

I take my reliever inhaler *only if I need*. My reliever inhaler is: (insert name/colour)

I should take \_\_\_\_\_puff(s) of my reliever inhaler if any of these things happen:

- I'm wheezing
- My chest feels tight
- I'm finding it hard to breathe
- I'm coughing.

Other medicines I should take for my asthma every day: (free text)

With this daily routine I should expect/aim to have no symptoms.

## **The Green Zone**

Reminds daily prescribed preventer inhaler to increase adherence

Reinforces that salbutamol inhaler is only for symptom relief

## Associated co-morbidities require treatment



#### WHEN I FEEL WORSE

- My symptoms are coming back (wheeze, tightness in my chest, breathlessness, cough)
- I am waking up at night
- My symptoms are interfering with my usual day-today activities (e.g. at work, exercising, housechores)
- I am using my reliever inhaler \_\_\_\_\_ times a week or more
- If I am told to monitor my peak flow and it drops to below \_\_\_\_\_

#### Preventer inhaler

- If I have <u>not</u> been using my preventer inhaler, start using it regularly again.
- Increase my preventer inhaler to \_\_\_\_\_ puffs \_\_\_\_ times a day for 2 weeks.

#### <u>Reliever inhaler</u>

- Ventolin MDI: up to \_\_\_\_ puffs every \_\_\_\_ hours
- Symbicort: 1 puff as needed up to a total 12 puffs/day

#### Standby prednisolone

If I have been given standby prednisolone (steroid) tablets to keep at home: take \_\_\_\_ mg of prednisolone immediately and every morning for 5 days

If I do not improve within 24 hours, I should visit a doctor for further advice.

Alternatively, I may also contact the asthma nurse (at \_\_\_\_\_\_within office hours) for further advice before seeing a doctor

## **The Yellow Zone**

Described acute loss of asthma control

ICS dose needs to be increased during this time

Salbutamol = 800mcg/day Formoterol = 72 mcg/day

OCS and contacting a healthcare provider.



#### IN AN ASTHMA ATTACK

- My reliever inhaler is not helping or I need it more than every \_\_\_\_\_ hours
- I find it difficult to walk or talk
- I find it difficult to breathe
- I'm wheezing a lot or I have a very tight chest or I'm coughing a lot
- If I am told to monitor my peak flow and it drops to below \_\_\_\_\_

#### THIS IS AN EMERGENCY. PLEASE TAKE THE FOLLOWING ACTION NOW:

- 1. Sit up straight. Try to keep calm.
- Take 2 puffs of my reliever inhaler every 5minutes up to a maximum of 10 puffs
- If I do not feel better after 10 puffs, or if I feel worse at any point in time, I need to get to the nearest doctor or hospital.
- 4. Call 995 for an ambulance if needed.

## The Red Zone

Recognise dangerous symptoms in an exacerbation.

# Crisis management and calling for help.



General Hospital

# Why?





**Cochrane** Database of Systematic Reviews

Self-management education and regular practitioner review for adults with asthma (Review)


Gibson PG, Powell H, Wilson A, Abramson MJ, Haywood P, Bauman A, Hensley MJ, Walters EH, Roberts JJL



- 36 randomised controlled trials
- 6090 participants
- Compared self-management vs usual asthma care
- Patient outcomes
- Healthcare Consumption

18 studies included action plan as part of self-management strategy

#### Figure 2. Forest plot of comparison: I Self Management versus Usual Care, outcome: I.I Hospitalisations (% subjects hospitalised).



#### Figure 3. Forest plot of comparison: I Self Management versus Usual Care, outcome: 1.3 ER Visits (% subjects).

:	Self Manage	ement	Usual C	are		Risk Ratio	Risk Ratio
Study or Subgroup	Events		Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.3.1 Optimal Self Mana	gement						
Cote 1997	18	50	25	54	6.8%	0.78 [0.49, 1.24]	
Cowie 1997	5	46	19	48	5.3%	0.27 [0.11, 0.67]	
Ghosh 1998	60	140	68	136	19.6%	0.86 [0.66, 1.11]	
Heard 1999	3	97	1	94	0.3%	2.91 [0.31, 27.45]	
Ignacio-Garcia 1995	18	35	18	35	5.1%	1.00 [0.63, 1.58]	
Levy 2000	36	103	39	108	10.8%	0.97 [0.67, 1.39]	
Moudgil 2000	8	304	12	289	3.5%	0.63 [0.26, 1.53]	
Yoon 1993	3	28	7	28	2.0%	0.43 [0.12, 1.49]	
Zeiger 1991	33	149	53	160	14.5%	0.67 [0.46, 0.97]	
Subtotal (95% CI)		952		952	67.8%	0.78 [0.67, 0.91]	•
Total events	184		242				
Heterogeneity: Chi <sup>2</sup> = 11	.34, df = 8 (P	= 0.18);	I <b>²</b> = 29%				
Test for overall effect: Z =	= 3.21 (P = 0	.001)					
1.3.2 Self Monitoring an	d Regular R	eview					
Bailey 1990	17	124	16	101	5.0%	0.87 [0.46, 1.63]	
Garret 1994	85	251	82	249	23.3%	1.03 [0.80, 1.32]	_ <b>_</b>
Subtotal (95% CI)		375		350	28.3%	1.00 [0.79, 1.26]	★
Total events	102		98				1
Heterogeneity: Chi <sup>2</sup> = 0.2	25, df = 1 (P =	= 0.62); P	<sup>2</sup> = 0%				
Test for overall effect: Z =							
1.3.3 Self Monitoring On	ilv.						
Subtotal (95% CI)		0		0		Not estimable	
Total events	0	-	0	-			
Heterogeneity: Not appli							
Test for overall effect: No							
1.3.4 Regular Review Or	-		-	4.00	4.00	0.40 10.00 4.50	
Hilton 1986	1	86	6	100	1.6%	0.19 [0.02, 1.58]	
Shields 1986 Subtotal (05% CD	4	44 130	8	43 143	2.3% 3.9%	0.49 [0.16, 1.50] 0.37 [0.14, 0.99]	
Subtotal (95% CI)	-	130		145	3.9%	0.57 [0.14, 0.99]	
Total events	5		14				
Heterogeneity: Chi <sup>2</sup> = 0.6			•= 0%				
Test for overall effect: Z =	= 1.98 (P = 0.	.05)					
Total (95% CI)		1457		1445	100.0%	0.82 [0.73, 0.94]	•
Total events	291		354				
Heterogeneity: Chi <sup>2</sup> = 16	.92, df = 12 (	P = 0.15	); I <sup>z</sup> = 299	6			0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z =			-				0.1 0.2 0.5 1 2 5 10 Favours Self M'gment Favours Usual Care
	<b>.</b>						Favours Sell Wignient Favours Osual Care





	6.05
Chapter 4. Management of worsening asthma and exacerbations	
Overview	
Diagnosis of exacerbations	
Self-management of exacerbations with a written asthma action plan	
Management of asthma exacerbations in primary care	
Management of asthma exacerbations in the emergency department	82



### Are Asthma Medications and Management Related to Deaths from Asthma?

MICHAEL J. ABRAMSON, MICHAEL J. BAILEY, FIONA J. COUPER, JAN S. DRIVER, OLAF H. DRUMMER, ANDREW B. FORBES, JOHN J. McNEIL, E. HAYDN WALTERS and the Victorian Asthma Mortality Study Group

Departments of Respiratory, Forensic, and Epidemiology and Preventive Medicine, and Victorian Institute of Forensic Medicine, Monash University, Southbank, and Monash Medical School, The Alfred Hospital, Melbourne, Australia



#### TABLE 4

#### RISK OF DEATH ASSOCIATED WITH SELECTED MANAGEMENT FEATURES AND ASTHMA MEDICATIONS ADJUSTED FOR DEMOGRAPHIC AND PSYCHOSOCIAL FACTORS AND DISEASE SEVERITY\*

Predictor	Adjusted OR	95% CI
Used peak flow meter in last year	0.65	0.2-2.3
Written asthma action plan	0.29	0.09-0.93
Verbal instructions only	1.3	0.51-3.2
Usual oral steroid in last month	4.1	1.7–10.3
Usual nebulised symptomatic medication	4.2	1.8–9.9
Used nebulized symptomatic medication either usually during the last month or for an attack	4.3	1.7–11.0
Used inhaled symptomatic medication for an attack	0.43	0.16-1.13
Used inhaled preventive medication for an attack	0.66	0.29-1.5
Used oral steroid for an attack	0.09	0.02-0.33
Used oral steroid either usually during the last month or for an attack	0.71	0.32-1.6



**Cochrane** Database of Systematic Reviews

## Personalised asthma action plans for adults with asthma (Review)

Gatheral TL, Rushton A, Evans DJW, Mulvaney CA, Halcovitch NR, Whiteley G, Eccles FJR, Spencer S



- 15 randomised controlled trials
- 3062 participants
- Compared <u>action plan + education vs</u> <u>education</u> alone

- Patient outcomes
- Healthcare Consumption

#### PAAP plus education compared with education alone for adults with asthma

#### Patient or population: adults with asthma Setting: Community, secondary care, tertiary care Intervention: PAAP plus education Comparison: education alone

Outcomes			Relative effectNumber of participantsQu(95% CI)(studies)(G		Quality of the evidence (GRADE)	Comments
	Risk with education alone	Risk with PAAP plus education				
Exacerbation requiring ED or hospitalisation.	265 per 1000.	280 per 1000 (89 to 609)	OR 1.08 (0.27 to 4.32)	70 (1 RCT)	⊕⊖⊖⊖ VERY LOW <sup>a</sup>	No clear benefit or harm of PAAP plus educa- tion (very low-quality evidence). Risk with ed- ucation alone based on 12 months before study start
	Mean asthma control, change from baseline in ACQ score was -0.29		-	70 (1 RCT)	⊕⊕⊖⊖ LOW <sup>b</sup>	No clear benefit or harm of PAAP plus education (low-quality evidence). MCID for ACQ (0.5) not reached
Serious adverse events (including death).	Included studies reporte	ed no data for this outcom	10.			
	Mean quality of life, change from baseline in AQLQ score was 0.3	-	-	174 (1 RCT)	⊕⊕⊖⊖ LOW <sup>c</sup>	No clear benefit or harm of PAAP plus education (low-quality evidence). MCID for AQLQ (0.5) not reached

# HOW?





#### Changi General Hospital SingHealth

#### WRITTEN ASTHMA ACTION PLAN (WAAP)

WHEN I FEEL WORSE
<ul> <li>My symptoms are coming back (wheeze, tightness in my chest, breathlessness, cough)</li> <li>I am waking up at night</li> </ul>
<ul> <li>My symptoms are interfering with my usual day-to- day activities (e.g. at work, exercising, housechores)</li> <li>I am using my reliever inhaler times a week or more</li> </ul>
<ul> <li>If I am told to monitor my peak flow and it drops to below</li> </ul>
Preventer inhaler
If I have <u>not</u> been using my preventer inhaler, start using it regularly again.
Increase my preventer inhaler to puffs times a day for 2 weeks.
<u>Reliever inhaler</u>
Ventolin MDI: up to puffs every hours
Symbicort: 1 puff as needed up to a total 12 puffs/day
Standby prednisolone
If I have been given standby prednisolone (steroid) tablets to keep at home: take mg of prednisolone immediately and every morning for 5 days
If I do not improve within 24 hours, I should visit a doctor for further advice.
Alternatively, I may also contact the asthma nurse (at within office hours) for further advice before seeing a doctor

al

#### WHEN I FEEL WORSE

- My symptoms are coming back (wheeze, tightness in my chest, breathlessness, cough)
- I am waking up at night
- My symptoms are interfering with my usual day-today activities (e.g. at work, exercising, housechores)
- I am using my reliever inhaler \_\_\_\_\_ times a week or more
- If I am told to monitor my peak flow and it drops to below \_\_\_\_\_

#### Preventer inhaler

- If I have <u>not</u> been using my preventer inhaler, start using it regularly again.
- Increase my preventer inhaler to \_\_\_\_\_ puffs \_\_\_\_ times a day for 2 weeks.

#### <u>Reliever inhaler</u>

- Ventolin MDI: up to \_\_\_\_ puffs every \_\_\_\_ hours
- Symbicort: 1 puff as needed up to a total 12 puffs/day

#### Standby prednisolone

If I have been given standby prednisolone (steroid) tablets to keep at home: take \_\_\_\_ mg of prednisolone immediately and every morning for 5 days

If I do not improve within 24 hours, I should visit a doctor for further advice.

Alternatively, I may also contact the asthma nurse (at \_\_\_\_\_\_within office hours) for further advice before seeing a doctor

## **The Yellow Zone**

Described acute loss of asthma control

ICS dose needs to be increased during this time

Salbutamol = 800mcg/day Formoterol = 72 mcg/day

OCS and contacting a healthcare provider.



## **Yellow Zone Triggers**

#### WHEN I FEEL WORSE

- My symptoms are coming back (wheeze, tightness in my chest, breathlessness, cough)
- I am waking up at night
- My symptoms are interfering with my usual day-today activities (e.g. at work, exercising, housechores)
- I am using my reliever inhaler \_\_\_\_\_ times a week or more
- If I am told to monitor my peak flow and it drops to below \_\_\_\_\_

## **Symptoms**

## Peak flow less than 80% of personal

best

		Item	Price	Shipping	Rating Q·lounge	
Hush Puppies'		Microlife Microlife PF 100 Peak Flow Meter for Spirometry with FEV1	<mark>\$</mark> 75.00	<ul> <li>✗ \$1.99</li> <li>Free on condition \$50.00</li> <li>■■ US</li> </ul>	NEW Cart Qpost	
Polo Shirt \$19.90 Beauty GRAND		Quest AsthmaMD Lung Performance Peak Flow Meter	<b>\$67.20</b> \$134.40	¥ \$5.80~ ™ CN	Viewed List Size Guide	
SALE!	3	Microlife, PF 100 Peak Flow Meter for Spirometry with FEV1, White/Blue	<b>\$114.00</b> \$228.00	¥ Free ■ US		
DOVE Nutritive Solutions Shampoo \$12.90		Omron PF9940 PeakAir Peak Flow Meter	\$47.00	¥ \$1.99 Free on condition \$50.00	NEW	
ELIZABETH ARDEN Ceramide Cansulas	PERSONAL AND A SUBJECT OF A SUB	AnchorWell Digital Peak Flow Meter for Asthma and COPD Lung Performance Measure Peak Expiratory Flow	\$103 00	★ \$1.99 Free on condition \$50.00	Changi General Hospit	al



**Cochrane** Database of Systematic Reviews

# Options for self-management education for adults with asthma (Review)

Powell H, Gibson PG




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Hospitalisation (subjects)	4	412	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [0.44, 3.12]
2 Hospitalisations (mean)	2	229	Mean Difference (IV, Fixed, 95% CI)	-0.04 [-0.13, 0.05]
3 ER Visits (subjects)	5	512	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.61, 1.35]
4 ER Visits (mean)	2	229	Mean Difference (IV, Fixed, 95% CI)	-0.04 [-0.17, 0.09]
5 Dr Visits (subjects)	2	161	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.78, 1.10]
6 Days off Work (mean)	2	229	Mean Difference (IV, Fixed, 95% CI)	1.96 [-0.44, 4.36]
7 Oral Corticosteroid Courses	2	152	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.82, 2.87]



Eur Respir J 2013; 41: 53–59 DOI: 10.1183/09031936.00205911 Copyright©ERS 2013

## Early detection of asthma exacerbations by using action points in self-management plans

Persijn J. Honkoop\*<sup>,#</sup>, D. Robin Taylor<sup>¶</sup>, Andrew D. Smith<sup>¶</sup>, Jiska B. Snoeck-Stroband\* and Jacob K. Sont\*



Worsened symptoms + PEFR <80% predicts exacerbation with 100% sensitivity and 87% specificity.



#### Preventer inhaler

If I have <u>not</u> been using my preventer inhaler, start using it regularly again.

Increase my preventer inhaler to \_\_\_\_\_ puffs \_\_\_\_ times a day for 2 weeks.

 ${}^{\circ}$ 

**Increase ICS** how many times? **High-dose ICS? ICS/LABA** 

## inhalers?



## How much ICS to increase?



### At least 2x for 7 to 14 days

ARTICLES

## Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial

Lancet 2004; 363: 271-75

ASTHMA

T W Harrison, J Oborne, S Newton, A E Tattersfield

Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations

J M FitzGerald, A Becker, M R Sears, S Mink, K Chung, J Lee, and the Canadian Asthma Exacerbation Study Group

Thorax 2004;59:550-556. doi: 10.1136/thx.2003.014936



### Quadrupling the Dose of Inhaled Corticosteroid to Prevent Asthma Exacerbations

A Randomized, Double-blind, Placebo-controlled, Parallel-Group Clinical Trial

Janet Oborne<sup>1</sup>, Kevin Mortimer<sup>1</sup>, Richard B. Hubbard<sup>2</sup>, Anne E. Tattersfield<sup>1</sup>, and Tim W. Harrison<sup>1</sup>

<sup>1</sup>Division of Respiratory Medicine and <sup>2</sup>Division of Epidemiology and Public Health, Respiratory Biomedical Research Unit, University of Nottingham, Nottingham, United Kingdom Am J Respir Crit Care Med Vol 180. pp 598–602, 2009

To be enrolled, participants had to give written informed consent, be taking a maintenance dose of inhaled corticosteroid between 200 and  $1,000 \mu g$  beclometasone dipropionate (or equivalent) per day, have

## Low-dose + Moderate-dose ICS



Study inhalers started




TABLE 2. PRIMARY AND SECONDARY OUTCOMES

	Active	Placebo	Risk Ratio (95% CI)	P Value
Number randomized	197	206		
Number requiring oral corticosteroids	18	29	0.64 (0.37 to 1.11)	0.11
Number who started the study inhaler	56	38	-	
Number requiring oral corticosteroids	12	19	0.43 (0.24 to 0.78)	0.004

Changi

**General Hospital** 

*Figure 2.* Mean fall in PEF (95% confidence interval) expressed as a percentage fall from the mean baseline PEF value (*dashed line*, active; *solid line*, placebo). Includes participants who started oral cortico-steroids.

	Low dose	Moderate do			Link dece
		moderate do			High dose
Beclometasone di	propionate <sup>1</sup>				
Standard particle CFC-free inhalers	200–500 micrograms per day in 2 divided doses	600–1,000 m per day in 2 d doses		ams	1,200–2,000 micrograms per day in 2 divided doses
Extra-fine particle CFC-free inhalers²	100–200 micrograms per day in 2 divided doses	300–400 mic day in 2 divid		is per ses	500–800 micrograms per day in 2 divided doses
Budesonide					
Dry powder inhalers	200–400 micrograms per day as a single dose or in 2 divided doses		600–800 mic day as a sing in 2 divided d <del>oses</del>		uuses
Ciclesonide					
Metered dose inhaler	80–160 micrograms per day as a single dose	240–320 micrograms per day as a single dose or in 2 divided doses			400–640 micrograms per day in 2 divided doses
Fluticasone propie	onate				
Metered dose and dry powder inhalers <sup>3</sup>	100–250 micrograms per day in 2 divided doses	300–500 micrograms per day in 2 divided doses			600–1,000 micrograms per day in 2 divided doses
Fluticasone furoat	te <sup>4</sup>				
Dry powder inhaler	-	100 microgran single daily do		a	200 micrograms as a single daily dose



Changi General Hospital

Oral prednisolone 1mg/kg for 3 to 5 days.

## What about ICS-LABA inhalers?



ICS-Formoterol preparations - Up to a maximum of 72 mcg of formoterol/day

#### **ICS-non-Formoterol preparations**





Salmeterol, olodaterol, indacaterol, vilanterol

# 1.? Exceed the regulatory limit 2.Commence oral prednisolone 3.Provide an ICS-only inhaler for yellow zone



#### Reliever inhaler

Ventolin MDI: up to \_\_\_\_ puffs every \_\_\_\_ hours

Symbicort: 1 puff as needed up to a total 12 puffs/day

#### Standby prednisolone

If I have been given standby prednisolone (steroid) tablets to keep at home: take \_\_\_\_ mg of prednisolone immediately and every morning for 5 days

If I do not improve within 24 hours, I should visit a doctor for further advice.

Alternatively, I may also contact the asthma nurse (at \_\_\_\_\_within office hours) for further advice before seeing a doctor

#### 800 mcg/day

72 mcg/day


1mg/kg IBW

#### Contact your healthcare provider



# Modes?











#### AsthmaMD<sup>TT</sup>Track. Control. Live Better.





## Readability, Suitability, and Characteristics of Asthma Action Plans: Examination of Factors That May Impair Understanding



WHAT'S KNOWN ON THIS SUBJECT: National asthma treatment guidelines include the recommendation that all asthma patients receive a written asthma action plan. No previous study has sought to examine the readability, suitability, and content of asthma action plans within a nationally representative sample.

*Pediatrics* 2013;131:e116–e126

**AUTHORS:** H. Shonna Yin, MD, MS,<sup>a</sup> Ruchi S. Gupta, MD,<sup>b</sup> Suzy Tomopoulos, MD,<sup>a</sup> Michael S. Wolf, PhD, MPH,<sup>c</sup> Alan L. Mendelsohn, MD,<sup>a</sup> Lauren Antler, BA,<sup>a</sup> Dayana C. Sanchez, BA,<sup>a</sup> Claudia Hillam Lau, BA,<sup>d</sup> and Benard P. Dreyer, MD<sup>a</sup>

<sup>a</sup>Department of Pediatrics, New York University School of Medicine and Bellevue Hospital Center, New York, New York; <sup>b</sup>Department of Pediatrics. and <sup>c</sup>Health Literacv and Learning



#### TABLE 2 Suitability of Written Asthma Action Plans<sup>a</sup>

Recommended criteria	Mean (SD)	Range	Not suitable	Adequate	
			n (%)	n (%)	
Content <sup>a</sup>					
Purpose explicitly stated	0.27 (0.45)	0-1	22 (73.3)	8 (26.7)	
Content aimed at desirable behaviors/actions	1.0 (0)	1-1	0 (0)	30 (100)	
Scope limited to essential information	0.97 (0.18)	0-1	1 (3.3)	29 (96.7)	
Content, composite	0.74 (0.17)	0.33-1	1 (3.3)	29 (96.7)	
Literacy demand <sup>b</sup>					
Writing style conversational, uses active voice, simple sentences	0.87 (0.35)	0-1	4 (13.3)	6 (86.7)	
Vocabulary uses common words	0.77 (0.43)	0-1	7 (23.3)	23 (76.7)	
Context given first before new information	0.93 (0.25)	0-1	2 (6.7)	28 (93.3)	
Learning aided by "road signs"/advanced organizers	0.80 (0.41)	0-1	6 (20.0)	24 (80.0)	
Literacy demand, composite	0.84 (0.21)	0.25-1	1 (3.3)	29 (96.7)	
Graphics					
Graphics simple, uses line drawings/sketches; likely to be familiar to reader <sup>d</sup>	0.96 (0.20)	0–1	1 (4.0)	24 (96.0)	
Illustrations relevant; key messages presented visually in an effective manner <sup>d</sup>	0.92 (0.28)	0–1	2 (8.0)	23 (92.0)	
Purpose and use of lists, tables, graphics explained	0.67 (0.48)	0-1	10 (33.3)	20 (66.7)	
Explanatory captions used for graphics <sup>e</sup>	0.63 (0.50)	0-1	6 (37.5)	10 (62.5)	
Graphics, composite	0.75 (0.30)	0-1	4 (13.3)	26 (86.7)	
Layout and typography					
Layout factors optimized <sup>f</sup>	0.70 (0.47)	0-1	9 (30.0)	21 (70.0)	
Typography optimized <sup>g</sup>	0.70 (0.47)	0-1	9 (30.0)	21 (70.0)	
Subheadings or "chunking" used to group ideas	0.50 (0.51)	0-1	15 (50.0)	15 (50.0)	
Layout and typography, composite	0.63 (0.29)	0-1	9 (30.0)	21 (70.0)	
Learning stimulation/motivation					
Interactiveness promoted by presenting problems / questions	0.37 (0.49)	0-1	19 (63.3)	11 (36.7)	
for reader response					
Behaviors are modeled and specific	0.97 (0.18)	0-1	1(3.3)	29 (96.7)	
Motivation / self-efficacy encouraged by subdividing topics into	0.67 (0.48)	0-1	10 (33.3)	20 (66.7)	
small, learnable parts					
Learning stimulation/motivation, composite	0.67 (0.25)	0.33-1	8 (26.7)	22 (73.3)	
Overall suitability category <sup>h</sup>	0.74 (0.14)	0-1	0 (0)	30 (100.0)	
Any unsuitable score	NA	NA	12 (40.0) <sup>i</sup>	18 (60.0) <sup>j</sup>	


# Special groups to consider



## Illiterate








Roberts, Dr Nicola & Evans, David & Blenkhorn, Paul & R Partridge, Martyn. (2009). Development of an electronic pictorial asthma action plan and its use in primary care. Patient education and counseling. 80. 141-6. 10.1016/j.pec.2009.09.040.



- •Adolescents
- Busy professional







**Cochrane** Database of Systematic Reviews

# Smartphone and tablet self management apps for asthma (Review)

Marcano Belisario JS, Huckvale K, Greenfield G, Car J, Gunn LH



Smartphone apps compared with paper-based	ased diaries for asthma self management			
Patient or population: patients with clinici Settings: primary and tertiary care Intervention: smartphone app for asthma Comparison: paper-based diaries for asthm				
Outcomes	Effects of smartphone apps for asthma self management	No of participants (studies)	Quality of the evidence (GRADE)	
Symptom scores Asthma Control Questionnaire (ACQ) - 6- item version Mean differences in scores at 6 months	One study found no statistically significant difference in the mean difference in ACQ scores between the intervention and con- trol group at 6 months (MD 0.01, 95% CI - 0.23 to 0.25)		⊕⊕⊖⊖ low¹	
Patients with unscheduled visits to the emergency department 6-month follow-up	One study found that participants in the in- tervention group were less likely to attend the emergency department than those in the control group (OR 0.20, 95% CI 0.04 to 0.99). Another study found no statis- tically significant difference between the intervention and control groups (Fisher's exact test $P = 0.12$ )		⊕⊕⊖⊖ low <sup>1</sup>	
Hospital admissions 6-month follow-up	None of the included studies found a statis- tically significant difference between the intervention and control groups (Fisher's exact test yielding a one-sided P = 0.52; OR 3.07 (95% CI 0.32 to 29.83))	(2 studies)	⊕⊕⊖⊖ low¹	
<b>GP consultations for asthma</b> 6-month follow-up	One study did not find a statistically signif- icant difference between the intervention and control groups (OR 1.40, 95% Cl 0.85 to 2.31)		⊕⊕⊖⊖ low <sup>1</sup>	Changi General Hospital

# Achieving Successful

# implementation



### Asthma Knowledge Among Adult Asthmatic Outpatients in a Tertiary Care Hospital

ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2004) 22: 81-89

Shu Ming Chai, Keng Leong Tan, Jesline Liling Wong and Philip Eng

 Cross-sectional study performed in specialist outpatient clinic

#### Written asthma action plan ownership

Only 17.0% of subjects reported having a written action plan to guide them when they suffered from an asthma attack. The majority (67%) responded in the negative and 15 (16%) were not sure if they had received one. Those who had

- 94 outpatients



al Hospital

# A qualitative study of factors influencing family physicians' prescription of the Written Asthma Action Plan in primary care in Singapore

Tan N C, Tay I H, Ngoh A, Tan M



- Physician uncertainty due to training and exposure
- Perceived ineffectiveness

- Relying on nurses to administer
- Perceived non-compliance and language barrier

Lost to follow-up



Ring et al. Trials 2012, 13:216 http://www.trialsjournal.com/content/13/1/216



#### RESEARCH

**Open Access** 

Developing novel evidence-based interventions to promote asthma action plan use: a cross-study synthesis of evidence from randomised controlled trials and qualitative studies

Nicola Ring<sup>1\*</sup>, Ruth Jepson<sup>1</sup>, Hilary Pinnock<sup>2</sup>, Caroline Wilson<sup>3</sup>, Gaylor Hoskins<sup>4</sup>, Sally Wyke<sup>5</sup> and Aziz Sheikh<sup>2</sup>




- Interval telephone reinforcements
- Internet-based asthma management tools for patients
- Software decision support systems for physicians
- Education seminars for physicians
- In clinic asthma education by nurses
- Pharmacy-based asthma service



### Spirometry Test At GPs in the East (ST@GE)

Bringing spirometry to the doorstep of the private GPs For more information, email us at <a href="mailto:stage@cgh.com.sg">stage@cgh.com.sg</a>







 Assess suitability for test
 Explain to patient<sup>#</sup>
 Service is at no cost to patient



Fill referral form



Fax to **62844197** or Email to <u>stage@cgh.com.sg</u>



\* For the test, to avoid inhaled bronchodilators (refer to details in page 3 of PIS)

\* Appointment is to be cancelled or rescheduled to another day if patient is late for 15 mins



On appointment day\*, patient shows up @ clinic, with inhaler, if any



Clinic staff reminds patient: 1. to arrive 10 mins before appointment time

 to avoid inhaled bronchodilators<sup>#</sup>

3. to bring inhaler, if any



Received appointment for Spirometry



• Thank You

